Xolair (omalizumab; Roche/Novartis) Drug Analysis 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Xolair" drug pipelines has been added to ResearchAndMarkets.com's offering.

Xolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin E (IgE) antibodies to the high affinity IgE receptors present on the surface of mast cells and basophils, thereby minimizing the allergic response. Xolair is available for subcutaneous administration.

Key Topics Covered:

1 Product Profiles

  • Xolair: Asthma

List of Figures

Figure 1: Asthma - current and future market dynamics analysis

Figure 2: The author's drug assessment summary of Xolair in asthma

Figure 2: The author's assessment summary of key marketed and pipeline drugs for asthma

Figure 3: Asthma sales across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Xolair drug profile

Table 2: Xolair pivotal trial data in asthma

Table 3: Xolair late-phase trial data in asthma

Table 4: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26

Companies Mentioned

  • Roche
  • Novartis

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bxhc3j/xolair?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs